Table 1.

Clinical observations from therapeutic drug monitoring of PS, PC, and plasminogen for selected patients on (a) steady‐state VKA (warfarin and phenprocoumon) compared to rivaroxaban, and (b) steady‐state VKA compared to enoxaparin therapy

a
Patient #	Laboratory values	Warfarin treatment	Enoxaparin treatment
1	Protein S, %	43	128
	Protein C, %	59	100
	Plasminogen, %	98	119
2	Protein S, %	59	117
	Protein C, %	41	112
	Plasminogen, %	113	148
3	Protein S, %	52	102
	Protein C, %	54	86
	Plasminogen, %	127	109
4	Protein S, %	52	111
	Protein C, %	63	100
	Plasminogen, %	120	124
5	Protein S, %	66	139
	Protein C, %	65	96
	Plasminogen, %	110	106

b
Patient #	Laboratory values	Warfarin treatment	Rivaroxaban treatment
1	Protein S, %	61	120
	Protein C, %	59	112
	Plasminogen, %	96	101
2	Protein S, %	49	149
	Protein C, %	61	137
	Plasminogen, %	114	120
3	Protein S, %	47	115
	Protein C, %	58	105
	Plasminogen, %	97	109
4	Protein S, %	62	103
	Protein C, %	58	107
	Plasminogen, %	–	–
5	Protein S, %	54	85
	Protein C, %	58	81
	Plasminogen, %	–	–